AROMASIN and tamoxifen are known as adjuvant medications. Adjuvant treatment is associated with breast cancer and is administered after surgery radiation or chemotherapy. These drugs are prescribed along with first-line cancer drugs. An earlier study had revealed that postmenopausal women with ER+ untimely breast cancer who were taking tamoxifen for 2 to 3 years switching to AROMASIN can help reduce the risk of recurrence more than relying on tamoxifen for 5 years. However no significant survival benefit was seen during the study.
A new study has found that cholesterol medicines known as "statins" may reduce the risk of strokes heart attacks and death by almost half when studied in patients with normal levels of cholesterol. With this finding at least 32 million people would be eligible for treatment. The drug studied is AstraZeneca Plc’s Crestor. The patients eligible for the study are those who have high amounts of a protein linked to inflammation.
Chantix or Varenicline is a well-known medication from Pfizer Incl. known to treat smoking addiction. It is considered as a substitute to nicotine replacement therapies (NRTs) like nicotine patches and agonist medication. The drug has an ability to lessen passion for cigarettes and other tobacco related products. This drug has also the potential of helping patients to stop smoking. It has proved greater effectiveness in comparable studies.